COVID-19 Wastewater Metrics Matched Clinical Case Counts in Early 2022
August 2nd 2023In a study conducted from January to September 2022, 268 United States counties within 22 states participated in the U.S. Centers for Disease Control and Prevention’s National Wastewater Surveillance System (NWSS).
Read More
Amid Favorable Results, Questions About Syfovre’s Safety | ASRS 2023
July 31st 2023The manufacturer has reported seven causes of retinal vasculitis associated with Syfovre. Results of an open-label, extension study presented at the American Society of Retina Specialists meeting today show favorable results among those who crossed over from sham to active treatment.
Read More
When a Biosimilar Might Increase Not Decrease Costs | Ravi Parikh, M.D., M.P.H., ASRS 2023
July 30th 2023The approval of an ophthalmic bevacizumab biosimilar might mean the end of low-cost, repackaged Avastin as an anti-VEGF treatment for retinal diseases, with the unintended consequence of adding $457 million to Medicare B spending.
Read More
The Anti-VEGF Biosimilars Paradox | Ravi Parikh, M.D., M.P.H., ASRS 2023
July 30th 2023In an interview with MHE, Parikh, a retina specialist in New York and director of healthcare delivery research for the Department of Ophthalmology at NYU Grossman School of Medicine, described the current situation of biosimilars in retinal medicine and the attitudes of retinal specialists about using the lower-cost alternatives.
Watch
The Response of New GA Therapies From Patients, Payers | ASRS 2023
July 30th 2023In an interview with MHE, Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, talked about the latest geographic atrophy treatments, pegcetacoplan and avacincaptad pegol, from a coverage and healthcare resource utilization standpoint, as both will potentially be available for the chronic disease that previously had no treatments.
Watch
Effectiveness of Pegcetacoplan, Avacincaptad Pegol in Geographic Atrophy Treatment | ASRS 2023
July 30th 2023Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, chatted with MHE about the latest geographic atrophy treatments and shared key takeaways found from clinical trials examining them. Hahn presented on macular degeneration today at the American Society of Retina Specialists annual meeting in Seattle.
Watch
The Long and Short (Interval Switch) of the PULSAR Trial | ASRS 2023
July 29th 2023About 20% of patients in the trial of a high-dose, longer-interval regimen of Eylea (aflibercept )switched to shorter intervals, according to data presented today at the American Society of Retinal Specialists annual scientific meeting, which is being held in Seattle. Researchers didn't find any clues as to why in their baseline characteristics.
Read More
A Primer on PULSAR | Keyvan Koushan, M.D., ASRS 2023
July 29th 2023In an interview with Managed Healthcare Executive prior to the meeting, Keyvan Koushan, M.D., a retina specialist at the Toronto Retina Institute and a lecturer in the Department of Ophthalmology and Vision Sciences at the University of Toronto, briefly described the design of the PULSAR trial and the positive results that have been reported so far.
Watch
Value in Health Care Act of 2023 Introduced to Congress to Reinforce Value-Based Care
July 29th 2023The Value in Health Care Act of 2023, a bipartisan legislation that would make several important reforms to ensure alternative payment models (APMs) continue to produce high quality care for the Medicare program and its beneficiaries, was introduced in a letter signed by seventeen of the nation’s leading stakeholders in healthcare.
Read More
FDA Update for the Week of July 24, 2023
July 29th 2023FDA approvals this week include the second nonprescription naloxone nasal spray for opioid overdose, the first drug for a skin infection from pox virus and a drug to treat an eye infection caused by mites. In addition, the FDA has accepted a supplemental application for Ofev in children with rare lung disease.
Read More
Re Syfovre: ‘It’s a Healthy Debate. It’s a Debate We Should Be Having’ | Charles Wykoff, M.D., Ph.D.
July 28th 2023Pros and cons of Syfovre (pegcetacoplan), the newly approved drug for geographic atrophy will be discussed at the American Society of Retinal Specialists annual scientific meeting in Seattle this weekend, predicts leading member of the society. Biosimilars are also on the agenda.
Read More
4 Highlights of the ASRS Annual Scientific meeting | Charles Wykoff, M.D., Ph.D.
July 28th 2023Charles Wykoff, M.D., Ph.D., director of clinical research at Retina Consultants of Texas, noted new treatments for geographic atrophy are predicted to be a hot topic at the American Society of Retina Specialists annual scientific meeting that starts today in Seattle.
Watch
Non-Profits Granted $11.1 Million by UnitedHealthcare to Increase Access to Care
July 27th 2023UnitedHealthcare is awarding $11.1 million in grants to 66 nonprofit organizations through its Empowering Health program across 12 states to help uninsured individuals and underserved communities.
Read More
New Study Aims to Decipher the Mystery of Vitiligo
July 26th 2023The study will enroll an estimated 1,000 patients, of whom approximately 200 will have vitiligo. The remaining participants will be at-risk family members, some 40 to 60 of whom are expected to develop vitiligo during the 5-year study.
Read More
FDA Updates for the Week of July 17, 2023
July 22nd 2023The FDA has cleared several new products this week, including the first monoclonal antibody for RSV in infants, a novel therapy for newly diagnosed patients with AML and a postexposure anthrax vaccine. Additionally, an FDA decision on donanemab for Alzheimer’s is expected by the end of this year.
Read More
Survey Finds Medicare Members Spend More on Healthcare Than Non-Medicare Members
July 21st 2023Medicare households spent an average of $6,557 on healthcare, accounting for 15% of their total household spending ($44,686), while non-Medicare households spent $4,598 on their healthcare, accounting for 7% of their total household spending ($67,769).
Read More
Can Medical Schools Help Improve Outcomes for Minorities Living with Diabetes?
July 21st 2023Professional development should take steps to incorporate outreach into medical school curriculums, say Rosemay Michel, D.P.M., and Gary M. Rothenberg, D.P.M. "Students must learn what motivates people to make healthy choices in their daily lives, including the influences of schools, faith-based groups, social media and extended family on personal decision-making," argue Michel and Rothenberg.
Read More
Johns Hopkins Tweaks Name of Health Insurance Plans To Reflect Large, Varied Roles
July 19th 2023In addition to a health plan for employees, Johns Hopkins Health Plans has a Medicare Advantage plan, a Medicaid managed care plan and a plan for the families of people who are on active duty in the U.S. military.
Read More
The Role of Digital Health In Treating OUD
July 19th 2023In a study recently published in the JAMA Network, researchers sought to investigate the use of patient-facing digital health technologies for opioid use disorder (OUD) by organizations in the United States with ACO contracts. The search began as it was unclear whether these technologies serve as substitute or complements to traditional SUD treatment resources in health care organizations.
Read More